Az Üzleti Sajtószolgálat (Original Text Service - OTS) üzleti vállakozások, cégek, intézmények közleményeit, tájékoztatóit, meghívóit, állásfoglalásait közli. Szolgáltatásunk segítségével több mint 2000 újságírót és kommunikációs szakembert érhet el könnyen, gyorsan és költséghatékonyan – az Ön által megfogalmazott sajtóközleményt változtatás nélkül juttatjuk el az MTI-előfizetők szerkesztőségi rendszerébe vagy igény szerint akár a külföldi sajtóhoz is. (Az OTS anyagai nem képezik az MTI-kiadás részét, a szó szerint továbbított szövegekért minden esetben a közlő a felelős.)
|
|
|
2023. december 19., kedd 13:00 |
LTS receives $4.3 Million grant for the development of contraceptive Microneedle Array Patches |
|
Andernach, 19 December, 2023 (APA/MTI) - LTS, a leading pharmaceutical technology company, announced today that it has received a grant from the Bill & Melinda Gates Foundation. The purpose of the grant is to support the development of microneedle array patches (MAP) for self-administration of contraceptives for women in low- and middle-income countries (LMICs). The grant will fund $4.3 million over a duration of 25 months. |
Poor access to contraceptives presents a significant burden for
women living in LMICs. According to a 2022 study, one in 14 women
worldwide who want to use contraceptives cannot access them*. This
amounts to an unmet need of 162 million women, the majority of whom
live in sub-Saharan Africa and South Asia.
MAPs are an innovative drug delivery technology that offers
advantages in comparison to established drug delivery applications
for contraception such as fewer side effects and potentially
improved bioavailability with therapeutic and cost benefits. The MAP
contraceptive is planned as a long-acting application (6 month). In
comparison to other existing long-acting forms it can be
self-administered, is discreet and does not require healthcare
provider visits.
Bas van Buijtenen, CEO of LTS, comments: "At LTS, we care
passionately about bringing patient friendly drug delivery to people
worldwide. We are honoured to receive support from the Gates
Foundation in creating solutions for populations that would
otherwise be at risk of being left behind. With this program, we aim
to deliver improved access to contraception, boosting health and
empowering women."
"The LTS MAP team is excited to have support from the Gates
Foundation for the development of a long-acting contraceptive
Microneedle Array Patch with LTS", said Dr. Frank Theobald, Head of
MAP Program at LTS. "LTS has made great progress recently with
respect to pre-clinical and clinical data, taking major steps
towards the up-scaling and commercialization of the MAP technology.
Based upon those progresses made, we would like to emphasize that
our MAP technology is no longer a vision, but real alternative for
drug delivery of small molecules, vaccines, biologics, and mRNA.
Support from the foundation will help to develop the MAP technology
further and bring it to the next level of maturity and it will allow
women in LIMCs to get access to a reliable and effective way of
contraception and improve their economic situation. That will
support them in establishment of gender equality in their
communities."
LTS has also received funding from the Bill & Melinda Gates
Foundation to support new formulation methods for mRNA, such as
dissolvable microneedle array patches.
About LTS We CARE. We CREATE. We DELIVER. The driving philosophy behind LTS.
As a trusted technology partner for the pharmaceutical industry, we
develop and manufacture innovative drug delivery systems such as
Transdermal Patches ("TTS") and Oral Thin Films ("OTF") as well as
wearable drug delivery devices ("OBDS"). LTS´ commercial offering
encompasses more than 20 marketed products and a diverse pipeline of
more than 40 development projects targeting multiple disease
indications. LTS's innovation pipeline contains both partner-funded
as well as proprietary, LTS-funded projects. LTS maintains its
leading position through the continuous refinement of its core TTS
and OTF technologies and by advancing emerging drug delivery
technologies, including Microneedle Array Patches ("MAP") for the
transdermal delivery of small and large molecules, biological
actives and vaccines. With its SorrelTM wearable drug delivery
platform LTS offers patient friendly solutions for complex drugs
delivery at home. Founded in 1984, LTS operates today from four
sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN,
USA and Netanya, Israel. LTS has also a representative office in
Shanghai, China.
Picture is available at AP
(https://apmultimedianewsroom.com/multimedia-newsroom/partners/news-aktuell)
*Haakenstad A, Angelino O, Irvine C, Bhutta ZA, Bienhoff K, Bintz
C, Causey K, Dirac MA, Fullman N, Gakidou E, Glucksman T, Hay SI,
Henry NJ, Martopullo I, Mokdad AH, Mumford JE, Lim SS, Murray CJL,
Lozano R. 2022. Measuring contraceptive method mix, prevalence, and
demand satisfied by age and marital status in 204 countries and
territories, 1970-2019: a systematic analysis for the Global Burden
of Disease Study 2019. Online: The Lancet. Available at:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00936-9/fulltext
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
|
|
|
|